Prognostic impact of p15 gene aberrations in acute leukemia

References

• Heerema NA, Sather HN, Sensel MG, et al. Association of chromosome arm 9p abnormalities with adverse risk in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood. 1999;94:1537–1544.
   PubMed Web of Science ®Google Scholar
• Hunter T, Pines J. Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell. 1994;79:573–582.
   PubMed Web of Science ®Google Scholar
• Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993;366:704–707.
   PubMed Web of Science ®Google Scholar
• Hannon GJ, Beach D. p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature. 1994;371:257–261.
   PubMed Web of Science ®Google Scholar
• Guan KL, Jenkins CW, Li Y, et al. Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev. 1994;8:2939–2952.
   PubMed Web of Science ®Google Scholar
• Chan FK, Zhang J, Cheng L, et al. Identification of human and mouse p19, a novel CDK4 and CDK6 inhibitor with homology to p16ink4. Mol Cell Biol. 1995;15:2682–2688.
   PubMed Web of Science ®Google Scholar
• Quelle DE, Zindy F, Ashmun RA, et al. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell. 1995;83:993–1000.
   PubMed Web of Science ®Google Scholar
• Fuxe J, Raschperger E, Pettersson RF. Translation of p15.5INK4B, an N-terminally extended and fully active form of p15INK4B, is initiated from an upstream GUG codon. Oncogene. 2000;19:1724–1728.
   PubMed Web of Science ®Google Scholar
• Tsubari M, Tiihonen E, Laiho M. Cloning and characterization of p10, an alternatively spliced form of p15 cyclin-dependent kinase inhibitor. Cancer Res. 1997;57:2966–2973.
   PubMed Web of Science ®Google Scholar
• Pasmant E, Laurendeau I, Heron D, et al. Characterization of a germ-line deletion, including the entire INK4/ARF locus, in a melanoma-neural system tumor family: identification of ANRIL, an antisense noncoding RNA whose expression coclusters with ARF. Cancer Res. 2007;67:3963–3969.
   PubMed Web of Science ®Google Scholar
• Lukas J, Parry D, Aagaard L, et al. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature. 1995;375:503–506.
   PubMed Web of Science ®Google Scholar
• Stott FJ, Bates S, James MC, et al. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 1998;17:5001–5014.
   PubMed Web of Science ®Google Scholar
• Lowe SW, Sherr CJ. Tumor suppression by Ink4a-Arf: progress and puzzles. Curr Opin Genet Dev. 2003;13:77–83.
   PubMed Web of Science ®Google Scholar
• Narita M, Nunez S, Heard E, et al. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell. 2003;113:703–716.
   PubMed Web of Science ®Google Scholar
• Humeniuk R, Rosu-Myles M, Fares J, et al. The role of tumor suppressor p15Ink4b in the regulation of hematopoietic progenitor cell fate. Blood Cancer J. 2013;3:e99.
   PubMed Web of Science ®Google Scholar
• Wolff L, Humeniuk R. Concise review: erythroid versus myeloid lineage commitment: regulating the master regulators. Stem Cells. 2013;31:1237–1244.
   PubMed Web of Science ®Google Scholar
• Rosu-Myles M, Taylor BJ, Wolff L. Loss of the tumor suppressor p15Ink4b enhances myeloid progenitor formation from common myeloid progenitors. Exp Hematol. 2007;35:394–406.
   PubMed Web of Science ®Google Scholar
• Teofili L, Morosetti R, Martini M, et al. Expression of cyclin-dependent kinase inhibitor p15(INK4B) during normal and leukemic myeloid differentiation. Exp Hematol. 2000;28:519–526.
   PubMed Web of Science ®Google Scholar
• Kotake Y, Nakagawa T, Kitagawa K, et al. Long non-coding RNA ANRIL is required for the PRC2 recruitment to and silencing of p15(INK4B) tumor suppressor gene. Oncogene. 2011;30:1956–1962.
   PubMed Web of Science ®Google Scholar
• van Zutven LJ, van DE, de Bont JM, et al. CDKN2 deletions have no prognostic value in childhood precursor-B acute lymphoblastic leukaemia. Leukemia. 2005;19:1281–1284.
   PubMed Web of Science ®Google Scholar
• Strefford JC, Worley H, Barber K, et al. Genome complexity in acute lymphoblastic leukemia is revealed by array-based comparative genomic hybridization. Oncogene. 2007;26:4306–4318.
   PubMed Web of Science ®Google Scholar
• Moreno TC, Widell S, Czader M, et al. Inverse correlation between Ink4-locus deletions and ICM-DNA hyperdiploidy in childhood acute lymphoblastic leukaemia, relation to clinical characteristics and outcome. Eur J Haematol. 2000;65:390–398.
   PubMed Web of Science ®Google Scholar
• Xu N, Li YL, Zhou X, et al. CDKN2 gene deletion as poor prognosis predictor involved in the progression of adult B-lineage acute lymphoblastic leukemia patients. J Cancer. 2015;6:1114–1120.
   PubMed Web of Science ®Google Scholar
• Usvasalo A, Savola S, Raty R, et al. CDKN2A deletions in acute lymphoblastic leukemia of adolescents and young adults: an array CGH study. Leuk Res. 2008;32:1228–1235.
   PubMed Web of Science ®Google Scholar
• Guidal-Giroux C, Gerard B, Cave H, et al. Deletion mapping indicates that MTS1 is the target of frequent deletions at chromosome 9p21 in paediatric acute lymphoblastic leukaemias. Br J Haematol. 1996;92:410–419.
   PubMed Web of Science ®Google Scholar
• Aguiar RCT, Sill H, Goldman JM, et al. The commonly deleted region at 9p21–22 in lymphoblastic leukemias spans at least 400 kb and includes p16 but not p15 or the IFN gene cluster. Leukemia. 1997;11:233–238.
   PubMed Web of Science ®Google Scholar
• Faderl S, Kantarjian HM, Manshouri T, et al. The prognostic significance of p16INK4a/p14ARF and p15INK4b deletions in adult acute lymphoblastic leukemia. Clin Cancer Res. 1999;5:1855–1861.
   PubMed Web of Science ®Google Scholar
• Iacobucci I, Ferrari A, Lonetti A, et al. CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients. Clin Cancer Res. 2011;17:7413–7423.
   PubMed Web of Science ®Google Scholar
• Atak ZK, Gianfelici V, Hulselmans G, et al. Comprehensive analysis of transcriptome variation uncovers known and novel driver events in T-cell acute lymphoblastic leukemia. PLoS Genet. 2013;9:e1003997.
   PubMed Web of Science ®Google Scholar
• Bertin R, Acquaviva C, Mirebeau D, et al. CDKN2A, CDKN2B, and MTAP gene dosage permits precise characterization of mono- and bi-allelic 9p21 deletions in childhood acute lymphoblastic leukemia. Genes Chrom Cancer. 2003;37:44–57.
   PubMed Web of Science ®Google Scholar
• Aggerholm A, Guldberg P, Hokland M, et al. Extensive intra- and interindividual heterogeneity of p15INK4B methylation in acute myeloid leukemia. Cancer Res. 1999;59:436–441.
   PubMed Web of Science ®Google Scholar
• Yu W, Gius D, Onyango P, et al. Epigenetic silencing of tumour suppressor gene p15 by its antisense RNA. Nature. 2008;451:202–206.
   PubMed Web of Science ®Google Scholar
• Nakamaki T, Kawamata N, Schwaller J, et al. Structural integrity of the cyclin-dependent kinase inhibitor genes, p15, p16 and p18 in myeloid leukaemias. Br J Haematol. 1995;91:139–149.
   PubMed Web of Science ®Google Scholar
• Cipolotti R, Lemos JA, Defavery R, et al. Inactivation of the p15 gene in children with acute lymphoblastic leukemia. Sao Paulo Med J. 2003;121:203–206.
   PubMedGoogle Scholar
• Takeuchi S, Bartram CR, Seriu T, et al. Analysis of a family of cyclin-dependent kinase inhibitors: p15/MTS2/INK4B, p16/MTS1/INK4A, and p18 genes in acute lymphoblastic leukemia of childhood. Blood. 1995;86:755–760.
   PubMed Web of Science ®Google Scholar
• Drexler HG. Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. Leukemia. 1998;12:845–859.
   PubMed Web of Science ®Google Scholar
• Calero Moreno TM, Gustafsson G, Garwicz S, et al. Deletion of the Ink4-locus (the p16ink4a, p14ARF and p15ink4b genes) predicts relapse in children with ALL treated according to the Nordic protocols NOPHO-86 and NOPHO-92. Leukemia. 2002;16:2037–2045.
   PubMed Web of Science ®Google Scholar
• Conceicao BT, Terra-Granado E, Quezado Magalhaes IM, et al. Frequency of copy number abnormalities in common genes associated with B-cell precursor acute lymphoblastic leukemia cytogenetic subtypes in Brazilian children. Cancer Genet. 2015;208:492–501.
   PubMed Web of Science ®Google Scholar
• Ribera J, Morgades M, Zamora L, et al. Prognostic significance of copy number alterations in adolescent and adult patients with precursor B acute lymphoblastic leukemia enrolled in PETHEMA protocols. Cancer. 2015;121:3809–3817.
   PubMed Web of Science ®Google Scholar
• Kim M, Yim SH, Cho NS, et al. Homozygous deletion of CDKN2A (p16, p14) and CDKN2B (p15) genes is a poor prognostic factor in adult but not in childhood B-lineage acute lymphoblastic leukemia: a comparative deletion and hypermethylation study. Cancer Genet Cytogenet. 2009;195:59–65.
   PubMed Web of Science ®Google Scholar
• Shimamoto T, Ohyashiki JH, Ohyashiki K. Methylation of p15(INK4b) and E-cadherin genes is independently correlated with poor prognosis in acute myeloid leukemia. Leuk Res. 2005;29:653–659.
   PubMed Web of Science ®Google Scholar
• Deneberg S, Grovdal M, Karimi M, et al. Gene-specific and global methylation patterns predict outcome in patients with acute myeloid leukemia. Leukemia. 2010;24:932–941.
   PubMed Web of Science ®Google Scholar
• Chim CS, Liang R, Tam CY, et al. Methylation of p15 and p16 genes in acute promyelocytic leukemia: potential diagnostic and prognostic significance. J Clin Oncol. 2001;19:2033–2040.
   PubMed Web of Science ®Google Scholar
• Chim CS, Lau JS, Wong KF, et al. CDKN2B methylation is an independent poor prognostic factor in newly diagnosed acute promyelocytic leukemia. Leukemia. 2006;20:149–151.
   PubMed Web of Science ®Google Scholar
• Teofili L, Martini M, Luongo M, et al. Hypermethylation of GpG islands in the promoter region of p15(INK4b) in acute promyelocytic leukemia represses p15(INK4b) expression and correlates with poor prognosis. Leukemia. 2003;17:919–924.
   PubMed Web of Science ®Google Scholar
• Matsuno N, Hoshino K, Nanri T, et al. Transcriptional repression of the p15 gene predicts the clinical outcome of acute myeloblastic leukemia with intermediate and adverse cytogenetics. Leukemia. 2004;18:1146–1148.
   PubMed Web of Science ®Google Scholar
• Yamada Y, Hatta Y, Murata K, et al. Deletions of p15 and/or p16 genes as a poor-prognosis factor in adult T-cell leukemia. J Clin Oncol. 1997;15:1778–1785.
   PubMed Web of Science ®Google Scholar
• Graf Einsiedel H, Taube T, Hartmann R, et al. Deletion analysis of p16(INKa) and p15(INKb) in relapsed childhood acute lymphoblastic leukemia. Blood. 2002;99:4629–4631.
   PubMed Web of Science ®Google Scholar
• Chim CS, Tam CY, Liang R, et al. Methylation of p15 and p16 genes in adult acute leukemia: lack of prognostic significance. Cancer. 2001;91:2222–2229.
   PubMed Web of Science ®Google Scholar
• Van Vlierberghe P, Ambesi-Impiombato A, De Keersmaecker K, et al. Prognostic relevance of integrated genetic profiling in adult T-cell acute lymphoblastic leukemia. Blood. 2013;122:74–82.
   PubMed Web of Science ®Google Scholar
• Quesnel B, Guillerm G, Vereecque R, et al. Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood. 1998;91:2985–2990.
   PubMed Web of Science ®Google Scholar
• Tien HF, Tang JL, Tsay MC, et al. Methylation of the p15(INK4B) gene in myelodysplastic syndrome: it can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformation. Br J Haematol. 2001;112:148–154.
   PubMed Web of Science ®Google Scholar
• Aggerholm A, Holm MS, Guldberg P, et al. Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients. Eur J Haematol. 2006;76:23–32.
   PubMed Web of Science ®Google Scholar
• Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia. 2003;17:1813–1819.
   PubMed Web of Science ®Google Scholar
• Hoshino K, Asou N, Okubo T, et al. The absence of the p15INK4B gene alterations in adult patients with precursor B-cell acute lymphoblastic leukaemia is a favourable prognostic factor. Br J Haematol. 2002;117:531–540.
   PubMed Web of Science ®Google Scholar
• Grovdal M, Karimi M, Khan R, et al. Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy. Br J Haematol. 2010;150:293–302.
   PubMed Web of Science ®Google Scholar
• Au WY, Fung AT, Ma ES, et al. Serial studies of methylation of CDKN2B and CDKN2A in relapsed acute promyelocytic leukaemia treated with arsenic trioxide. Br J Haematol. 2005;131:632–635.
   PubMed Web of Science ®Google Scholar
• Markus J, Garin MT, Bies J, et al. Methylation-independent silencing of the tumor suppressor INK4b (p15) by CBFbeta-SMMHC in acute myelogenous leukemia with inv(16). Cancer Res. 2007;67:992–1000.
   PubMed Web of Science ®Google Scholar
• Frommer M, McDonald LE, Millar DS, et al. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci USA. 1992;89:1827–1831.
   PubMed Web of Science ®Google Scholar
• Clark SJ, Harrison J, Paul CL, et al. High sensitivity mapping of methylated cytosines. Nucleic Acids Res. 1994;22:2990–2997.
   PubMed Web of Science ®Google Scholar
• Dodge JE, List AF, Futscher BW. Selective variegated methylation of the p15 CpG island in acute myeloid leukemia. Int J Cancer. 1998;78:561–567.
   PubMed Web of Science ®Google Scholar
• Tessema M, Langer F, Dingemann J, et al. Aberrant methylation and impaired expression of the p15(INK4b) cell cycle regulatory gene in chronic myelomonocytic leukemia (CMML). Leukemia. 2003;17:910–918.
   PubMed Web of Science ®Google Scholar
• Brakensiek K, Wingen LU, Langer F, et al. Quantitative high-resolution CpG island mapping with pyrosequencing reveals disease-specific methylation patterns of the CDKN2B gene in myelodysplastic syndrome and myeloid leukemia. Clin Chem. 2007;53:17–23.
   PubMed Web of Science ®Google Scholar
• Cameron EE, Baylin SB, Herman JG. p15(INK4B) CpG island methylation in primary acute leukemia is heterogeneous and suggests density as a critical factor for transcriptional silencing. Blood. 1999;94:2445–2451.
   PubMed Web of Science ®Google Scholar
• Raj K, John A, Ho A, et al. CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine. Leukemia. 2007;21:1937–1944.
   PubMed Web of Science ®Google Scholar
• Hasegawa D, Manabe A, Kubota T, et al. Methylation status of the p15 and p16 genes in paediatric myelodysplastic syndrome and juvenile myelomonocytic leukaemia. Br J Haematol. 2005;128:805–812.
   PubMed Web of Science ®Google Scholar
• Preisler HD, Li B, Chen H, et al. P15INK4B gene methylation and expression in normal, myelodysplastic, and acute myelogenous leukemia cells and in the marrow cells of cured lymphoma patients. Leukemia. 2001;15:1589–1595.
   PubMed Web of Science ®Google Scholar
• Melki JR, Vincent PC, Clark SJ. Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia. Cancer Res. 1999;59:3730–3740.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Dunbar A, Gondek LP, et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood. 2009;113:1315–1325.
   PubMed Web of Science ®Google Scholar
• Figueroa ME, Skrabanek L, Li Y, et al. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood. 2009;114:3448–3458.
   PubMed Web of Science ®Google Scholar
• Gutierrez MI, Siraj AK, Bhargava M, et al. Concurrent methylation of multiple genes in childhood ALL: correlation with phenotype and molecular subgroup. Leukemia. 2003;17:1845–1850.
   PubMed Web of Science ®Google Scholar
• Turker MS. Gene silencing in mammalian cells and the spread of DNA methylation. Oncogene. 2002;21:5388–5393.
   PubMed Web of Science ®Google Scholar
• De Braekeleer M, De Braekeleer E, Douet-Guilbert N. Whole genome/exome sequencing in acute leukemia: from research to clinics. In: Wu W, Choudhry H, editors. Next generation sequencing in cancer research. Volume 2: From basepairs to bedsides. Cham, Switzerland: Springer Publisher; 2015. p. 381–400.
   Google Scholar
• Hess CJ, Errami A, Berkhof J, et al. Concurrent methylation of promoters from tumor associated genes predicts outcome in acute myeloid leukemia. Leuk Lymphoma. 2008;49:1132–1141.
   PubMed Web of Science ®Google Scholar
• Ekmekci CG, Gutierrez MI, Siraj AK, et al. Aberrant methylation of multiple tumor suppressor genes in acute myeloid leukemia. Am J Hematol. 2004;77:233–240.
   PubMed Web of Science ®Google Scholar
• Galm O, Wilop S, Luders C, et al. Clinical implications of aberrant DNA methylation patterns in acute myelogenous leukemia. Ann Hematol. 2005;84:39–46.
   PubMed Web of Science ®Google Scholar
• Fry DW, Harvey PJ, Keller PR, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004;3:1427–1438.
   PubMed Web of Science ®Google Scholar
• Christman JK. 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene. 2002;21:5483–5495.
   PubMed Web of Science ®Google Scholar
• Leone G, Voso MT, Teofili L, et al. Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS. Clin Immunol. 2003;109:89–102.
   PubMed Web of Science ®Google Scholar
• Wong IH, Ng MH, Huang DP, et al. Aberrant p15 promoter methylation in adult and childhood acute leukemias of nearly all morphologic subtypes: potential prognostic implications. Blood. 2000;95:1942–1949.
   PubMed Web of Science ®Google Scholar
• Sakaguchi H, Muramatsu H, Okuno Y, et al. Aberrant DNA methylation is associated with a poor outcome in juvenile myelomonocytic leukemia. PLoS One. 2015;10:e0145394.
   PubMed Web of Science ®Google Scholar
• Zhou M, Gu L, Yeager AM, et al. Incidence and clinical significance of CDKN2/MTS1/P16ink4A and MTS2/P15ink4B gene deletions in childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol. 1997;14:141–150.
   PubMed Web of Science ®Google Scholar
• Mirebeau D, Acquaviva C, Suciu S, et al. The prognostic significance of CDKN2A, CDKN2B and MTAP inactivation in B-lineage acute lymphoblastic leukemia of childhood. Results of the EORTC studies 58881 and 58951. Haematologica. 2006;91:881–885.
   PubMed Web of Science ®Google Scholar